BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1481 related articles for article (PubMed ID: 17409799)

  • 1. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
    Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
    J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
    Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
    Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
    Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
    Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
    J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
    Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
    Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
    Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
    J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
    Socinski MA; Rosenman JG; Schell MJ; Halle J; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
    Cancer; 2000 Aug; 89(3):534-42. PubMed ID: 10931452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
    Stinchcombe TE; Lee CB; Moore DT; Rivera MP; Halle J; Limentani S; Rosenman JG; Socinski MA
    J Thorac Oncol; 2008 Nov; 3(11):1279-85. PubMed ID: 18978563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
    Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
    Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer.
    Choy H; DeVore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; LaPorte K; Johnson DH
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-21-S12-26. PubMed ID: 9331115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
    Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
    J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer.
    Deutsch M; Crawford J; Leopold K; Wolfe W; Foster W; Herndon J; Blackwell S; Yost R
    Cancer; 1994 Aug; 74(4):1243-52. PubMed ID: 8055445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.